ALTUVIIIO™ approved by the U.S. FDA: this positive event triggers impairment reversal, positively impacting 2022 IFRS net income; no change on business net income (non-IFRS)GlobeNewsWire • 02/24/23
Press release: New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe diseaseGlobeNewsWire • 02/24/23
Press Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protectionGlobeNewsWire • 02/23/23
Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock TopplesInvestors Business Daily • 02/03/23
Press Release : Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestoneGlobeNewsWire • 02/03/23
Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitisGlobeNewsWire • 01/30/23
Regeneron, Sanofi's Dupixent is one step closer to approval for young children in EuropeMarket Watch • 01/27/23